By SIRION Biotech…
To get in touch with Viral vector specialist SIRION Biotech heading to ECC2015 Vienna, simply fill out the form below.
Subscribe to Supplier
Viral vector specialist SIRION Biotech heading to ECC2015 Vienna
Martinsried, Germany: – Leading viral vector specialist SIRION Biotech will attend Europe’s largest cancer conference, September’s European Cancer Congress in Vienna.
SIRION will exhibit its versatile service portfolio for adeno-, lenti- and adeno-associated viruses (AAVs) as well as advanced viral vector technologies on its exhibition stand, Booth 1110 at the Messe Wien conference center.
Advanced viral platforms
You will have the option to discuss leading-edge viral vector platforms and functionally tested virus particles.
“The ECCO Congress is an important event for us. More than 75 per cent of our clients work in oncology research and this is a great opportunity to meet them and to exchange latest developments in this specialized field,” said Dr. Carl J. Christel, SIRION’s Senior Manager for Sales & Marketing.
Rapid growth of interest in viral vector technologies has fuelled impressive expansion at SIRION Biotech .The company’s revenues have been increasing at around 40 per cent annually since it began operating in 2007.
SIRION Biotech has established itself as the leading viral vector technology provider in Europe with more than 500 single projects and more than 150 repeat clients in recent years. Earlier this year, SIRION increased its North American presence in Boston, USA.
About SIRION Biotech
SIRION BIOTECH is Europe’s leading commercial supplier of viral vectors used for genetic research, target validation, gene therapy and vaccination studies.
In business since 2007, SIRION’s mission has been to change the paradigm for viral vector technologies. It has the ability to develop and supply all common viral vector types (adenovirus, lentivirus and AAV) available within a matter of weeks at titers and in the quantities required for preclinical experimentation.
The company also offers a full range of virus related services, ranging from particle production to virus driven cell modeling and medical R&D cooperations.
SIRION offerings include the transformational RNAiONE™ knockdown validation platform.
SIRION’s core expertise lies in custom virus generation for genetic engineering of mammalian cell systems. With its comprehensive viral vector portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application.
The 18th annual European Cancer Congress (ECC2015) is a five day event that opens September 25 at the Messe Wien Conference Center in Vienna. It is one of the lagest oncology-focused events in Europe.
The Brussels-based European Cancer Organization (ECCO) organizes the Congress, which this year will cover a broader agenda than ever before, ranging from basic and translational cancer research through to the latest results from phase III clinical trials. The Congress features a higher than average proportion of highly topical presentations, thanks to the ECCO late-breaking submissions policy.
The 2015 event will include integrated sessions and tracks on immunotherapy, young oncologists, and clinical trial design and regulatory affairs.
More information at: http://www.europeancancercongress.org/Event-Overview